MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Slides:



Advertisements
Similar presentations
OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.
Advertisements

A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access site.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
[name of file], 1 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director,
A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement.
Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.
CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.
1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Transradial Best Practices for Radial Access
My Best Radial Case of the Past Year ... And what I learned from it
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Leveraging Bayesian Methodology to Increase the Trial Efficiency
David E. Kandzari, MD on behalf of the BIONICS investigators
Disclosure Statement of Financial Interest
Randomized vs. Observational Studies: Strengths and Weaknesses
Clinical Trials and Outcomes with DES in CTO Revascularization
Regulatory Perspectives on Real World Evidence (RWE)
How To Minimize Bleeding In The Cath Lab
Pros and Cons of Radial Access
Regulatory Basics: Europe and the CE Mark
5 Different Observational Datasets: Pros & Cons
OUS Data: What does the CE Mark Really Mean?
Impact of Radial Access on Bleeding
Updates From NOTION: The First All-Comer TAVR Trial
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Use of Prior Information (Clinical, Pre-clinical and Models) to Improve Efficiency and the Efficacy Estimates Roseann M. White, MA Director of Clinical.
Claret Cerebral Protection Device: Implications of the Sentinel Study
Should We Preload STEMI Patients with Antiplatelet Therapy?
Renal Denervation Next Steps
Japan-USA Synergies: Academic View
Early Feasibility Studies Investigator Perspective
Surgical Mitral Valve Repair: What is the Gold Standard?
First-in-Man, First In The USA: What’s The Difference?
Obligatory Drug-Device Interactions-Why The Critical Path
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Transradial Approach for the Female Sex
Why Radial Access Should be the Default for Women undergoing PCI?
Disclosure Statement of Financial Interest
The TREAT Study: Can Devices Lower Bleeding Rates?
Kirk N Garratt MSc MD FSCAI
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
FAVOR II Europe-Japan FAVOR II E-J
OCT-Guided PCI What needs to be done to establish criteria?
Transradial Intervention as Access of Choice in STEMI
Radial vs Femoral Access in ACS Patients
Lessons Learned Through HBD: The Regulator’s View - US FDA
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
How to Minimize Bleeding in STEMI Patients Outline: -Know about bleeding -Think about consequences of bleeding -Identify bleeding risk factors -Maximize.
CIT 2018 Template Title 40 pt Bold Arial
A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.
CIT 2018 Template Title 40 pt Bold Arial
EDUCATE: A NESTcc Demonstration Project Regulatory Perspective
How and why this study may change my practice ?
CIT 2017 Template Title 40 pt Bold Arial
CIT 2018 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
Disclosure Statement of Financial Interest
Disclosure Statement of Financial Interest
CIT 2018 Template Title 40 pt Bold Arial
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Study of Access For Enhancement of STEMI for Seniors: The SAFE STEMI for Seniors Protocol Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company Names

Conflicts No personal stock, holdings or IP No corporate revenue >$50k per annum Research grants, consulting relationships: Abbott Vascular Acist Medical Biosensors Boston Scientific Cook Medical Cordis J&J CSI Medtronic OrbusNeich St. Jude Medical Terumo

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet What is SAFE STEMI for Seniors? Combining public health and regulatory science A new approach to STEMI in seniors: 100% STEMI, 100% “radial first” strategy Prospective RCT: IRA-only vs. complete revasc A new approach to medical device trials: Registry-based randomized trials: less site based work load faster enrollment More efficient regulatory decisions: complementary clinical questions for labelling (IDE) partnered manufacturer-sponsors MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Why SAFE STEMI for Seniors? SENIORS: The Role of Age in STEMI Complications from STEMI: Highest mortality Highest MACE rates Complications from therapies: Bleeding rates Vascular complications Other peri-procedural complications Complications with billable (Medicare) services Claims data documentation MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Ready for prime time? Ready for seniors? …..in the USA??? “Radial-first” STEMI Ready for prime time? Ready for seniors? …..in the USA??? MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

RIVAL: 5,063 non-STEMI, 1,958 STEMI RIFLE STEACS: 1,000 STEMI MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Jolly SS et al Lancet 2011 Romagnoli E et al JACC 2013

MATRIX: ACS (STEMI & Non-STEMI) MACE NET DEATH 8,404 patients RCT TRI vs TFI Numerically lower MACE & mortality Significantly lower Net clinical benefit BARC Valmigli M et al, Lancet 2015;385:2465-76

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Novel Trial Structure 21st Century Regulatory Science: Registry-based randomized trials The NEST Context MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet National Evaluation System for Health Tech (NEST) Real World Evidence of Device Benefit/Risk, Safety Krucoff MW, Normand SL et al, JAMA 2015 Shuren J, Califf R, JAMA Published online July 11, 2016 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

TCT 2013 Featured LBCT A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches In Women Undergoing Percutaneous Coronary Intervention: The Study of Access Enhancement of PCI for Women (SAFE-PCI for Women) Trial Sunil V. Rao MD, Connie N. Hess MD, Britt Barham, Laura H. Aberle, Kevin Anstrom PhD, Tejan B. Patel MD, Jesse P. Jorgensen MD, Ernest L. Mazzaferri MD, Sanjit S. Jolly MD, Alice Jacobs MD, L. Kristin Newby MD, C. Michael Gibson MD, David F. Kong MD, Roxana Mehran MD, Ron Waksman MD, Ian C. Gilchrist MD, Brian J. McCourt, Eric D. Peterson MD MPH, Robert A. Harrington MD, Mitchell W. Krucoff MD on behalf of the SAFE-PCI for Women Investigators

SAFE-PCI for Women workflow Randomization Demographics Medical Hx Procedural data Index Hosp MACE Autopopulate Part 11 Compliant 65% site coordinator workload reduction Unique pages for trial Analytic Database

Efficiency Accelerates Enrollment

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet September 2013 Lauer M et al, NEJM 2013 Hess C et al, Am Heart J 2013 MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Rao S et al JACC Cardiovascular Int 7(8)2014

SAFE STEMI for Seniors: Study Design IDE

Patient Flows IDE MV PCI in STEMI PRAMI CvLPRIT

SAFE STEMI for Seniors: Linked NCDR-Claims Data “CRN” Structure Index Procedure Clinical Follow-up: Administrative Data n=1,000 Safety evaluation of Edwards Sapien heart valve in general practice Follow-up to 5 years: Detailed registry follow-up for year 1 Medicare claims follow-up for full time interval Comparator: Objective Performance Criteria (OPC) based on prior trial data Innovations in Efficient follow-up for post-market studies: Algorithm-assisted endpoints Medicare linkage This study will require patient-level consent because of the need for additional clinical follow-up that was considered outside the standard of care. 2 Registry-sponsored observational IDE studies are under review with FDA for label extension. These were designed to only include ‘standard of care’ clinical follow-up & may not require individual patient-level consent. CRF data from Clinical Registry Index AMI Hospitalization 1mo 1 yr 2 yrs 3 yrs 4 yrs 5 yrs Months

SAFE STEMI for Seniors: Conclusions Public health clinical trial: Radial access PCI in seniors Multivessel PCI in seniors Partnered manufacturer IDE: DES labelling for STEMI (Medtronic) iFR guided multivessel PCI (Volcano-Philips) 21st Century regulatory science Registry-based (CRN) RCT: Index procedure (NCDR Cath-PCI) Long term follow up (Claims data) MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

What is SAFE STEMI for Seniors? Public health clinical trial: >65 y.o STEMI <6 hrs Radial access PCI in seniors Multivessel PCI in seniors IDE(s) clinical trial: DES labelling for STEMI (Medtronic) iFR guided multivessel PCI (Volcano-Philips) Registry-based CRN randomized trial: Index procedure (NCDR Cath-PCI) Long term follow up (Claims data) Lesson in partnered problem solving MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet Study of Access For Enhancement of STEMI for Seniors: The SAFE STEMI for Seniors Protocol Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet